False-Positive and False-Negative Drug Tests

An unexpected drug-test result is not automatically a laboratory error—and it should not automatically be accepted without review. The first step is to identify whether the result is an initial screen, a confirmed analytical finding, or a final verified result.

This article is part of Drug-Test Detection and Accuracy.

What is a false positive?

A false positive occurs when a test classifies a specimen as positive even though the target condition is not present as defined. Initial immunoassay screens can produce presumptive positives because of cross-reactivity. That is one reason well-designed programs use specific confirmation before a high-consequence final decision.

People often call any disputed result a false positive, but a confirmed drug may be analytically correct while its source or medical significance remains disputed. Those are different questions.

What is a false negative?

A false negative occurs when the target is present within the intended scope but the test classifies the specimen as negative. Possible contributors include collection timing, analyte concentration below the cutoff, poor assay sensitivity for a particular drug, specimen problems, degradation, or an analyte not included in the panel.

Common sources of unexpected results

  • the ordered panel did not include the drug of interest;
  • a class immunoassay had cross-reactivity or limited sensitivity;
  • the specimen was collected too early or after the detection window;
  • the concentration was below the program cutoff;
  • a prescribed medication or metabolite explained the finding;
  • the specimen was dilute, invalid, adulterated, or substituted;
  • collection, identity, transport, or reporting errors occurred; or
  • the result was misunderstood—for example, a screen was treated as confirmed.

Why confirmation matters

Mass-spectrometry confirmation identifies defined analytes more specifically and resolves many immunoassay cross-reactions. It does not correct an uncollected specimen, wrong identity, incomplete panel, or invalid interpretation, so chain of custody and review still matter.

Medication lists found online

Lists of medicines said to “cause false positives” are often oversimplified. Cross-reactivity depends on the exact assay and may have been corrected in newer versions. Ask the laboratory or Medical Review Officer about the specific method, then compare the medication with the confirmed analyte.

What to do after an unexpected positive

  1. Ask whether the result is presumptive, confirmed, or verified.
  2. Obtain the specimen type, analyte, cutoff, and collection date.
  3. Use the authorized medical-review channel for prescriptions and products.
  4. Check chain-of-custody and specimen-validity information when applicable.
  5. Meet deadlines for split-specimen testing, retesting, or appeal.

What to do after an unexpected negative

Verify that the drug and relevant metabolite were actually included, that the assay can detect them, and that timing and cutoff support detection. In clinical care, discuss adherence and timing without assuming diversion or deception. Definitive testing may be appropriate if the result will change care.

Can a new specimen disprove the original?

Not necessarily. A later specimen reflects a different time and may have a different concentration. Testing a retained or split portion of the original specimen is often more directly relevant, when the program provides that option. Follow the applicable procedure rather than arranging an unrelated test without understanding its evidentiary value.

Continue with Retesting and Split-Specimen Procedures.

Sources

Last evidence review: October 29, 2026.